# NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

> **NCT03232424** · PHASE1 · COMPLETED · sponsor: **Hackensack Meridian Health** · enrollment: 12 (actual)

## Conditions studied

- Glioblastoma, Adult

## Interventions

- **DEVICE:** NovoTTF-200A
- **DRUG:** Temozolomide
- **RADIATION:** 3D conformal or intensity modulated radiation therapy (IMRT)

## Key facts

- **NCT ID:** NCT03232424
- **Lead sponsor:** Hackensack Meridian Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-26
- **Primary completion:** 2022-12-07
- **Final completion:** 2022-12-07
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03232424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03232424, "NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03232424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*